Status: Recruiting
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain lymphomas. Patients will either receive myeloablative conditioning or reduced intensity conditioning regimen prior to the transplant. Patients will be followed for 56 days for safety endpoints and remain in follow-up for one year.
Participants needed: 12
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Ossium Health, Inc.Updated: Feb 24, 2026Locations: 9
Eligibility criteria
Patient has the ability to provide informed consent according to the applicable... [+12]
Availability of suitable graft from living donor (defined as 7/8 or 8/8 HLA-matc... [+5]